6 days Ago By ABMN Staff
Renaissance Technologies LLC boosted its position in shares of Pulmonx Co. ( NASDAQ:LUNG – Free Report ) by 38.7% during the 4th quarter, HoldingsChannel reports.
The fund owned 220,510 shares of the company’s stock after buying an additional 61,500 shares during the quarter. Renaissance Technologies LLC’s holdings in Pulmonx were worth $1,497,000 as of its most recent filing with the Securities & Exchange Commission. Several other large investors have also recently added to or reduced their stakes in the company.
JPMorgan Chase & Co. raised its stake in shares of Pulmonx by 2.4% in the third quarter.
JPMorgan Chase & Co. now owns 1,055,522 shares of the company’s stock valued at $8,750,000 after purchasing an additional 25,002 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Pulmonx by 1.
1% in the 4th quarter. Geode Capital Management LLC now owns 902,240 shares of the company’s stock valued at $6,128,000 after buying an additional 9,454 shares in the last quarter. Franklin Resources Inc.
lifted its holdings in shares of Pulmonx by 2.3% during the 3rd quarter. Franklin Resources Inc.
now owns 700,389 shares of the company’s stock worth $5,806,000 after acquiring an additional 15,570 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Pulmonx by 0.
8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 315,532 shares of the company’s stock valued at $2,142,000 after acquiring an additional 2,363 shares in the last quarter.
Finally, Norges Bank bought a new stake in Pulmonx in the fourth quarter valued at about $1,027,000. Institutional investors and hedge funds own 91.04% of the company’s stock.
Analysts Set New Price Targets A number of research analysts have commented on the stock. D. Boral Capital initiated coverage on shares of Pulmonx in a research note on Monday, March 10th.
They set a “buy” rating and a $17.00 price target for the company. Citigroup began coverage on Pulmonx in a research report on Monday, March 10th.
They set a “buy” rating for the company. Morgan Stanley started coverage on Pulmonx in a research report on Monday, March 10th. They issued an “equal weight” rating on the stock.
Finally, Jefferies Financial Group assumed coverage on Pulmonx in a report on Monday, March 10th. They set a “buy” rating for the company. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company.
According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $12.75. Insider Activity In other Pulmonx news, Director Glendon E.
French III sold 55,453 shares of the business’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $8.28, for a total transaction of $459,150.
84. Following the completion of the sale, the director now directly owns 1,011,974 shares of the company’s stock, valued at approximately $8,379,144.72.
The trade was a 5.20 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website .
Also, CEO Steven S. Williamson sold 27,689 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $7.
14, for a total transaction of $197,699.46. Following the sale, the chief executive officer now directly owns 194,342 shares of the company’s stock, valued at approximately $1,387,601.
88. This trade represents a 12.47 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . Insiders have sold 145,660 shares of company stock valued at $1,128,484 over the last three months. 6.
80% of the stock is owned by insiders. Pulmonx Trading Down 0.2 % LUNG stock opened at $5.
19 on Tuesday. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.
70 and a quick ratio of 6.77. The stock has a market capitalization of $208.
88 million, a price-to-earnings ratio of -3.60 and a beta of 0.61.
The business has a fifty day moving average price of $6.78 and a 200 day moving average price of $6.59.
Pulmonx Co. has a fifty-two week low of $4.15 and a fifty-two week high of $10.
01. Pulmonx ( NASDAQ:LUNG – Get Free Report ) last released its quarterly earnings results on Wednesday, February 19th. The company reported ($0.
33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12.
Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%.
The business had revenue of $23.77 million during the quarter, compared to analysts’ expectations of $22.29 million.
Analysts expect that Pulmonx Co. will post -1.55 EPS for the current fiscal year.
About Pulmonx ( Free Report ) Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. See Also Want to see what other hedge funds are holding LUNG? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Pulmonx Co. ( NASDAQ:LUNG – Free Report ). Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.
com's FREE daily email newsletter ..
